DIRS.INFO The most relevant business & tech news

☆ This rare muscle disease play can rally more than 50%, BofA says
▼ + stars: | 2024-05-03 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Avidity Biosciences stock has more room to run thanks to the company's pipeline of multiple treatments for rare muscle disorders, according to Bank of America. Avidity has a therapeutic platform — antibody oligonucleotide conjugates — that was well-received at the time it went public in 2020, Meacham said. But shares were hurt by a clinical hold on Avidity's leading program for treating an uncommon muscle disorder, DM1. The program, tested in the Marina trial, recently saw long-term data that has "helped lift that key overhang on the stock," Meacham said. Those catalysts are tied to two other drugs in the muscle disorder space that are expected to report data this year, according to Meacham.

Persons: Geoff Meacham, Meacham Organizations: Biosciences, Bank of America Locations: San Diego, Thursday's

☆ The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
▼ + stars: | 2024-04-04 | by ( William Edwards | ) www.businessinsider.com time to read: +5 min

Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.

Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ BofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesity
▼ + stars: | 2024-02-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesityGeoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes treatment, Mounjaro.

Persons: Geoff Meacham, Eli Lilly Organizations: Bank of America Securities

☆ These smaller stocks could see big gains in 2024, Bank of America says
▼ + stars: | 2024-01-30 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +5 min

Against this backdrop, Bank of America on Monday released a list of best small- and mid-cap ideas for 2024. Strategist Jill Carey Hall added that this year's basket of 31 stocks has average 12-month potential upside of 29%, and is slightly tilted towards value stocks over growth. Shares of Bath & Body Works have trailed the market, rising 2.4% in 2023 and 0.4% so far in 2024. Bank of America also named United Airlines one of its top SMID ideas for 2024. Other names on Bank of America's list of SMID picks included e-commerce retailer Wayfair and aircraft leasing company Air Lease .

Persons: That's, Russell, Jill Carey Hall, Lorraine Hutchinson, Hutchinson, BofA, Geoff Meacham, Lou Gehrig's, Meacham, CyberArk, Tal Liani, Liani, Max, Andrew Didora, UAL, Didora, — CNBC's Michael Bloom Organizations: Wall, Bank of America, Monday, Body, Pharmaceuticals, TAM, United Airlines, Boeing, Bank of, Air Lease Locations: U.S, Amylyx, cybersecurity, CY26, Chicago

☆ BofA's Geoff Meacham on Pfizer earnings: The story is still about Covid contraction
▼ + stars: | 2024-01-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA's Geoff Meacham on Pfizer earnings: The story is still about Covid contractionGeoff Meacham, Bank of America Securities senior pharmaceuticals analyst, joins 'Squawk Box' to break down Pfizer's quarterly earnings results, Big Pharma 2024 outlook, and more.

Persons: Geoff Meacham Organizations: Pfizer, Bank of America Securities, Big Pharma

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ BofA’S Meacham on what's next for Eli Lilly after FDA approves obesity drug
▼ + stars: | 2023-11-08 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBofA’S Meacham on what's next for Eli Lilly after FDA approves obesity drugGeoff Meacham, Bank of America, joins 'Fast Money' to talk the FDA's approval of Eli Lilly's obesity drug.

Persons: BofA’S Meacham, Eli Lilly, Geoff Meacham, Eli Organizations: Bank of America Locations: what's

☆ Expect Eli Lilly's momentum to continue, says Bank of America's Geoff Meacham
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailExpect Eli Lilly's momentum to continue, says Bank of America's Geoff MeachamGeoff Meacham, Bank of America senior pharmaceutical analyst, joins 'The Exchange' to discuss Eli Lilly's performance, the demand outlook for weight loss drugs, and more.

Persons: America's Geoff Meacham Geoff Meacham, Eli Lilly's Organizations: America's, Bank of America

☆ Buy this 'game-changer' biotech stock with more than 50% upside, BofA says
▼ + stars: | 2023-10-10 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Analyst Geoff Meacham's $18 price objective implies a potential upside of 51% from the stock's $11.94 closing price Monday. Meacham cited the firm's strong pipeline of novel drugs and treatments as a catalyst. Specifically, Neumora's navacaprant drug could be a "game-changer for major depressive disorder," Meacham said. "Overall, the diverse pipeline and targets provide multiple opportunities for Neumora to potentially become one of the largest neuro-focused biotech companies." While the company is currently unprofitable, Meacham expects this to change in 2027, or one year after the company officially commercializes navacaprant for major depressive disorders.

Persons: Geoff Meacham's, Meacham, — CNBC's Michael Bloom Organizations: Bank of America

☆ These are the food and snack companies most at risk as the new obesity drugs revolutionize consumer behavior, according to BofA
▼ + stars: | 2023-10-06 | by ( Alex Harring | ) www.cnbc.com time to read: +1 min

Food and snack companies may feel the most pressure as weight-loss drugs become more mainstream and affect consumer behaviors, according to Bank of America. Diabetes drugs that mimic gut hormones such as glucagon-like peptide-1, or GLP-1, have found new audiences in people looking to lose weight. In some instances, people taking these medicines have reported less of a hankering for unhealthy foods or alcohol and other drinks. Weight-management products such as shakes or frozen meals could also be pressured, Meacham added. CNBC Pro compiled some of the stocks that could be at risk that the firm is watching.

Persons: Geoff Meacham, Meacham, —, Michael Bloom Organizations: Bank of America, Diabetes, CNBC Pro Locations: LSEG

His most substantive comment on Trump’s myriad legal issues was a sarcastic remark about his mugshot in the Fulton County, Georgia, case. Defending democracy is an issue Biden allies believe remains deeply resonant with voters, almost three years after the 2020 contest. A White House official noted Arizona was a state that has toggled between Democratic and Republican leadership. “President Biden will talk about his conviction that we must not walk away from the sacrifices generations of Americans have made to defend our democracy,” the official said. “It’s well past time for President Biden to see the border crisis first hand and for the administration to do its job, secure the border, and keep Arizona safe.

Persons: Joe Biden, Donald Trump, he’s, MAGA, ” Biden, Sen, John McCain, “, ”, Biden, Joe Biden’s, Republican Sen, Trump, Hunter, –, “ I’m, “ MAGA, Jon Meacham, Thursday’s, – Biden, Biden harkened, McCain, McCain’s, Cindy, Katie Hobbs, Kyrsten Sinema –, Beau Organizations: Washington CNN, Republican Party, MAGA Republican, Department, Republican, Trump, White House, Biden, Gettysburg, McCain, White, GOP, Republicans, MAGA Republicans, Broadway, Democrats, Democratic, Democrat Locations: America, Arizona, Fulton County , Georgia, East, Tempe , Arizona, ”, Michigan, Chicago, Silicon Valley, Washington, Hanoi

☆ Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America
▼ + stars: | 2023-09-08 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The biopharmaceutical sector is poised to bounce back this year, and Gilead Sciences could be a key beneficiary, according to Bank of America. Analyst Geoff Meacham upgraded Gilead to buy from neutral. He increased his target price for the stock by $7 to $95, which suggests shares stand to gain 28.5% from where they closed Thursday. Shares of California-based Gilead have dropped 13.9% so far this year. "With the potential for broader interest in the sector, we are more optimistic on performance into 2H23," Meacham said.

Persons: Geoff Meacham, Meacham, biopharma, — Michael Bloom Organizations: Gilead Sciences, Bank of America, PrEP, Kite Pharma Locations: Gilead, California, HCV

☆ Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
▼ + stars: | 2023-06-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

The company's chief rival, Denmark-based Novo Nordisk (NVO), also published promising data on drugs in its pipeline, including its own oral weight-loss treatment. Other pharmaceutical companies are racing to compete with Novo Nordisk and Eli Lilly, including Amgen (AMGN) and Pfizer (PFE). Barclays on Tuesday projected Eli Lilly's three leading obesity-and-diabetes drugs could generate nearly $49 billion in combined sales in 2030. Eli Lilly Eli Lilly has multiple drugs in development that fall under the GLP-1 umbrella in various stages of clinical development. Novo Nordisk Novo Nordisk currently dominates the market for GLP-1 drugs, with three products in the class on the U.S. market already: Ozempic, Wegovy and Rybelsus.

Persons: It's, Eli Lilly, Eli Lilly's, retatrutide, Lilly, there's, Lilly's, Geoff Meacham, Eli Lilly Eli Lilly, Jim Cramer, Evan David Seigerman, —, — Morgan Stanley, Wegovy, Rybelsus, Jim Cramer's, Jim, Mike Segar Organizations: Club, Novo Nordisk, New England, of Medicine, American Diabetes Association, Pfizer, Reuters, Barclays, Bank of America, CNBC, JPMorgan, Drug Administration, Equity, BMO Capital, Novo Nordisk Novo Nordisk, GLP, FDA, Nordisk, Company Locations: San Diego, Denmark, GLP, It's, Novo, Novo Nordisk's, Branchburg , New Jersey

☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
▼ + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.

Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo

☆ Obesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA’S Meacham
▼ + stars: | 2023-06-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity weight loss market will remain a duopoly between Novo Nordisk and Eli Lilly: BofA’S MeachamGeoff Meacham, Bank of America Securities, joins 'Fast Money to discuss the state of the weight-loss drug market as Eli Lilly and Novo Nordisk compete for market share.

Persons: Eli Lilly, BofA’S Meacham Geoff Meacham Organizations: Novo Nordisk, Bank of America Securities

☆ New data fortifies Eli Lilly's standing in the burgeoning market for weight-loss drugs
▼ + stars: | 2023-06-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly (LLY) bolstered its position in the budding weight-loss drug market after new data showed its oral obesity pill was highly effective in a mid-stage study. Eli Lilly shares are taking a breather Monday, but we see no reason to join the sellers. Eli Lilly funded the trial. Eli Lilly stock is down about 1.3% Monday afternoon, likely on some profit-taking following a solid move up last week. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, LLY, orforglipron, Orforglipron, Eli Lilly's Mounjaro, Mounjaro, Jim Cramer, Lilly's, Geoff Meacham, Meacham, Lilly, It's, we've, Jim Cramer's, Jim, Cristina Arias Organizations: Club, New England, of Medicine, Nordisk, U.S . Food, Drug Administration, Novo Nordisk, Sunday, Bank of America, CNBC, UBS, Pfizer, Company, Pharmaceutical Locations: U.S, Alcobendas, Madrid, Spain

☆ Frank Ocean Pulls Out of Coachella, Citing Leg Injury
▼ + stars: | 2023-04-19 | by ( Julia Jacobs | ) www.nytimes.com time to read: +1 min

Frank Ocean will not perform at the Coachella Valley Music and Arts Festival this weekend because of a leg injury, a representative for the singer-songwriter said Wednesday, noting that the injury had prevented his performance there last Sunday from going on as planned. Later on, reports emerged that the set had been abruptly reconfigured ahead of the nighttime performance. The statement from Ocean’s representative, Anna Meacham, said that he had suffered a leg injury on the festival grounds days before his first scheduled performance, leading to the preshow scramble. “Frank Ocean was unable to perform the intended show but was still intent on performing, and in 72 hours, the show was reworked out of necessity,” the statement said. “On doctor’s advice, Frank Ocean is not able to perform weekend 2 due to two fractures and a sprain in his left leg.”

☆ Johnson & Johnson expects no new Covid vaccine revenue, after shots drive earnings beat
▼ + stars: | 2023-04-18 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

International Covid vaccine sales helped spark Johnson & Johnson 's revenue and earnings beat on Tuesday, but the company said it expects no sales from the shot moving forward. That marks the end of a rocky three years for J&J's Covid vaccine despite being one of the first shots to enter the U.S. market during the pandemic. Notably, all Covid vaccine revenue during the quarter came from outside of the U.S. JP Morgan analyst Chris Schott added that J&J's first-quarter beat was in part "driven by Covid vaccine upside." While J&J's vaccine fell out of favor in the U.S. and other wealthy countries, developing countries have continued to rely on it.

☆ Earnings playbook: Netflix and Goldman Sachs headline a big week of reports
▼ + stars: | 2023-04-16 | by ( Fred Imbert | ) www.cnbc.com time to read: +14 min

Tuesday Johnson & Johnson is set to report earnings before the open, followed by a call with management at 8:30 a.m. Goldman Sachs is set to report earnings before the open, followed by a call at 9:30 a.m. What history shows: Bespoke data shows Goldman tops earnings expectations 86% of the time. Netflix is set to report earnings after the bell, followed by a call with management at 6 p.m. Friday Procter & Gamble is set to report earnings before the open, with a conference call also slated for 8:30 a.m.

☆ Johnson & Johnson shares rise after company proposes baby powder cancer settlement
▼ + stars: | 2023-04-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson shares on Wednesday climbed after the company proposed paying $8.9 billion to settle thousands of claims that its baby powder and other talc products caused cancer. The pharmaceutical giant also said its subsidiary LTL Management refiled for Chapter 11 bankruptcy protection after its first attempt faced legal challenges. JPMorgan analyst Chris Schott on Thursday called the proposed settlement a positive for the company in a note. The proposed $8.9 billion settlement is also in-line with JPMorgan's $8 billion to $10 billion estimate, Schott noted. It's also unclear whether the proposed settlement will win approval in bankruptcy court, Bank of America analyst Geoff Meacham noted Thursday.

☆ Eli Lilly investors spooked by weak Mounjaro sales, but it's the obesity drug approval that will unlock its value
▼ + stars: | 2023-02-02 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Lilly said slightly more than 50% of commercial and Part D subscribers have access to the drug via their insurance plans. But new classes of weight loss medications are helping to change this mindset. Still, legislation will be necessary to get coverage of Mounjaro for obesity and overweight treatment by Medicare plans. By law, these plans are banned from paying for weight loss medications. Wegovy and Mounjaro One encouraging sign: Lilly competitor Novo Nordisk has gained access to more than 80% of insurance company formularies for their obesity treatment, Wegovy.

☆ Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken
▼ + stars: | 2023-01-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. Eli Lilly said it will keep working with the FDA to "evaluate the fastest pathway" for donanemab to reach patients. Indeed, analysts at Barclays wrote in a note to clients Thursday that "we now see [accelerated approval] off the table." LLY 1Y mountain Eli Lilly (LLY) 1-year performance "It's definitely not a thesis-breaker," Bank of America analyst Geoff Meacham told CNBC on Friday. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC

☆ Eli Lilly has spent years and billions of dollars in search of an effective Alzheimer's drug. But success is not all or nothing for the stock
▼ + stars: | 2023-01-09 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +22 min

Eli Lilly (LLY) has spent decades researching Alzheimer's disease without successfully bringing to market a treatment that slows the memory-destroying condition. For Eli Lilly as a company, an Alzheimer's drug is an important pursuit. Lilly's Alzheimer's history Eli Lilly's "first real foray" into Alzheimer's came in the 1990s, according to Dr. John Sims, Eli Lilly's head of medical development for donanemab. Financial implications for Lilly LLY mountain 2021-10-08 The Club started a new position in Eli Lilly (LLY) in October 2021. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

☆ Bank of America upgrades Merck, says pharma giant will outperform even as macro pressures mount
▼ + stars: | 2023-01-04 | by ( Sarah Min | ) www.cnbc.com time to read: +3 min

Investors can expect further gains from Merck this year, Bank of America said. Analyst Geoff Meacham upgraded shares to buy from neutral, saying the pharmaceutical company will continue to outperform even as macro pressures mount in 2023. Merck's core business in Keytruda continued to show strong performance, and it has several strategies in place for the loss of exclusivity. Loss of exclusivity is the set amount of time a pharmaceutical company can legally develop, sell and market a treatment. Keytruda is expected to be greater than 45% of Merck's total revenue in 2025, according to the note.

Search resuls for: "Meacham"

25 mentions found